Search

Copyright of Tianjin Medical Journal is the property of Tianjin Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Tianjin Medical Journal is the property of Tianjin Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the expression levels and clinical significance of (forkhead box Q1) FOXQ1 and E-cadherin in esophageal squamous cell carcinoma (ESCC). Methods Expression levels of FOXQ1 and E-cadherin were in ESCC tissues (ESCC group, n=42) and adjacent normal esophageal tissues (control group, n=42) were detected using immunohistochemistry. Correlations of FOXQ1 and E-cadherin expressions with clinical pathological parameters and prognosis were analyzed between two groups. Results The expression level of FOXQ1 was significantly higher in ESCC group than that in control group (64.29% vs 28.57%, χ²=5.384, P<0.05). The expression level of E-cadherin was significantly lower in ESCC group than that incontrol group (52.38% vs 90.48%, χ²=7.691, P<0.05). There were significant differences in FOXQ1 expressions between different TNM stages and whether lymph node metastasis is involved within ESCC group. There were significant differences in expression of E-cadherin between different tumor differentiation, depth of invasion, TNM stage and whether lymph node metastasis is involved within ESCC group. The expression of FOXQ1 was negatively correlated with E-cadherin in ESCC (r=-0.412, P < 0.05). The 5-year survival rates were significantly lower with high expression of FOXQ1 or with low expression of FOXQ1 (18.52% vs 66.67%, χ²=9.737, P < 0.05). The 5-year survival rates were significantly higher with high expression of E-cadherinor low expression of E-cadherin (59.09% vs 10.00%, χ²=10.996, P < 0.05). A multivariate Cox's proportional hazard regression analysis indicated that high FOXQ1 expression, low E-cadherin expression and lymph node metastasis were independent prognostic factors for ESCC. Conclusion The expression of FOXQ1 and E-cadherin showed a good correlation with ESCC. And examining expressions of both FOXQ1 and E-cadherin in ESCC may have practical values in estimating the prognosis of ESCC and directing future treatment. [ABSTRACT FROM AUTHOR]

Objective To investigate the clinical pathological features and prognosis of gastric carcinoma with neuroendocrine differentiation (NED) and mixed gonadal neuroendocrine carcinoma of the stomach (MANECs). Methods A retrospective analysis of 61 cases of gastric carcinoma with NED and 34 cases of MANECs and their histochemistry and immunohistochemistry were also observed. Prognosis of the 2 groups were compared by the Kaplan-Meiers survival analysis. Prognostic factors associated with patients with gastric cancer were analyzed by COX proportional hazards model. Results Tumor location, distant metastasis and lymph node metastasis were statistically different between these 2 groups (P < 0.05). Syn positive expression rate is higher than CgA and CD56 in the gastric carcinoma with NED group; Postoperative survive period of the gastric carcinoma with NED is shorter than that of MANECs (P < 0.05). Lymph node metastasis and distant regional transfer is obviously correlated with prognosis (P < 0.05). Conclusion Immunohistochemistry is important for the diagnosis of these two tumor. The number of neuroendocrine cells can help to assess prognosis and guide treatment. [ABSTRACT FROM AUTHOR]